Compare ELVR & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELVR | TBPH |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 890.2M | 993.7M |
| IPO Year | N/A | N/A |
| Metric | ELVR | TBPH |
|---|---|---|
| Price | $65.45 | $20.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $27.80 |
| AVG Volume (30 Days) | 82.4K | ★ 421.4K |
| Earning Date | 03-12-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.58 |
| Revenue | ★ $146,440,045.00 | $80,327,000.00 |
| Revenue This Year | $22.93 | $70.78 |
| Revenue Next Year | $7.27 | N/A |
| P/E Ratio | ★ N/A | $35.19 |
| Revenue Growth | 11.20 | ★ 27.12 |
| 52 Week Low | $15.55 | $7.90 |
| 52 Week High | $69.99 | $21.00 |
| Indicator | ELVR | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 64.21 |
| Support Level | N/A | $19.53 |
| Resistance Level | N/A | $21.00 |
| Average True Range (ATR) | 0.00 | 0.81 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 0.00 | 79.77 |
Elevra Lithium Ltd is a mineral exploration and development company. The principal activity of the company is the identification, acquisition, and evaluation of mineral exploration assets, focusing on lithium. The projects of the company include the Moblan Lithium Project, the Carolina Lithium Project, the Ewoyaa Lithium Project, North American Lithium, and other projects. The company also holds an interest in a tenement portfolio in the Pilbara region, prospective for gold and lithium.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).